Search

Researchers identify potential biomarkers of age-related macular degeneration

News

Findings may lead to earlier diagnoses and better prognostic information for patients — and, potentially, new pharmaceutical targets for AMD treatment. Boston, Mass. — Patients with any stage of age-related macular degeneration (AMD) carry signs of the...

Highlights from the 2017 Harvard Ophthalmology Annual Meeting and Alumni Reunion

News

Building diverse teams and collaborating across disciplines were overarching themes at the 2017 Harvard Ophthalmology Annual Meeting and Alumni Reunion, held June 23-24. More than 350 alumni, faculty, and trainees gathered in Boston for continuing medical...

Selecta Biosciences obtains exclusive license to proprietary gene therapy vector from Massachusetts Eye and Ear

News

Selecta is licensing Anc80 from Massachusetts Eye and Ear for a rare genetic disease with options on additional pre-specified indications. By combining Anc80 with Selecta’s investigational drug candidate, SVP-Rapamycin (SEL-110), Selecta is seeking to...

Diabetic Eye Disease

Page

Center of Excellence CO-DIRECTORS Lloyd Paul Aiello, MD, PhD Dean Eliott, MD MEMBERS See a list of Diabetic Eye Disease faculty Overview The Diabetic Eye Disease Center of Excellence aims to advance available treatments for diabetic retinopathy...

Drug-dispensing contact lens effectively lowers eye pressure in pre-clinical glaucoma model

News

A contact lens designed to deliver medication gradually to the eye may improve outcomes for patients who struggle with imprecise, difficult to self-administer eye drops Boston, Mass. — A contact lens designed to deliver medication gradually to the eye...

Lonza to Offer Novel Anc-AAV Gene Therapy Technology Through Exclusive Licensing Agreement with Massachusetts Eye and Ear

News

The strategic licensing agreement between Lonza and Massachusetts Eye and Ear® underscores Lonza’s position as a leading AAV manufacturing service provider and offers customers unprecedented technology and services to commercialize next generation gene...

Patients with High-Risk Macular Degeneration Show Improvement with High-Dose Statin Treatment

News

A phase I/II clinical trial at Massachusetts Eye and Ear found that some patients taking high doses of atorvastatin (cholesterol-lowering medication) had complete resolution of lipid deposits in the dry form of age-related macular degeneration (AMD). AMD...

Joan W. Miller, MD, FARVO Elected to the National Academy of Medicine

News

BOSTON (October 19, 2015) -- Joan Whitten Miller, MD, Henry Willard Williams Professor of Ophthalmology and Chair of Ophthalmology at Harvard Medical School, and Chief of Ophthalmology at Massachusetts Eye and Ear and Massachusetts General Hospital, has...

March 2014

News

NEWS | HONORS, AWARDS & GRANTS | PHILANTHROPY | PRESS | RECENT PUBLICATIONS | CALENDAR As we roll out this issue of Eye News on the heels of the 2014 Faculty Retreat, I wanted to thank our HMS Ophthalmology faculty for generously investing your time and...

Gene therapy restores hearing in deaf mice… down to a whisper

News

Improved delivery vector better penetrates the inner ear, also restores balance in a mouse model of Usher syndrome Boston, Mass. — In the summer of 2015, a team at Boston Children’s Hospital and Harvard Medical School reported restoring rudimentary...

Statement regarding first in-human clinical trial in inherited retinal degeneration (retinitis pigmentosa)

News

Mass. Eye and Ear and the Harvard Medical School Department of Ophthalmology are proud to be leading this important clinical trial. We look forward to reporting on safety and efficacy studies in the months and years to come. ReNeuron announces first...

eyeNews July/August 2014

News

NEWS | HONORS, AWARDS & GRANTS | PHILANTHROPY | PRESS | RECENT PUBLICATIONS | CALENDAR Welcome Aboard Trainees ! Our department is off to another great start for the 2014-2015 academic year. As we welcome new talent into our department—eight ophthalmology...